Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: Efficacy of hematopoietic stem cell transplantation

Haematologica

Volumn 99, Issue 12, 2014, Pages 1868-1875

  Kim, Sung Yong ^a,b   Le Rademacher, Jennifer ^c   Antin, Joseph H ^d   Anderlini, Paolo ^e   Ayas, Mouhab ^f   Battiwalla, Minoo ^g   Carreras, Jeanette ^c   Kurtzberg, Joanne ^h   Nakamura, Ryotaro ⁱ   Eapen, Mary ^c   Deeg, H Joachim ^a  

^a USA   (United States)

^b Konkuk University Hospital   (South Korea)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; CYTOGENETICS; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RELAPSE; SCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT; ALLOTRANSPLANTATION; ANEMIA, APLASTIC; CANCER STAGING; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE;

IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84919384670     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108977     Document Type: Article

References (28)

1. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program. 2012;292-300.
2. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012; 120(6):1185-96.
3. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003; 101(4):1236-42.
4. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcomes. JAMA. 2003; 289(9):1130-5.
5. Osugi Y, Yagasaki H, Sako M, Kosaka Y, Taga T, Ito T, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica. 2007;92(12): 1687-90.
6. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002; 100(3):786-90.
7. Afable MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:90-5.
8. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304(12): 1358-64.
9. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, et al. Chemotherapyonly compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002;16(9):1615-21.
10. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapyrelated myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010; 115(9):1850-7.
11. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379-87.
12. Kroger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwiesser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica. 2009;94(4):542-9.
13. Yoshimi A, Strahm B, Baumann I, Strahm B, Baumann I, Furlan I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myeloid leukemia following aplastic anemia. Biol Blood Marrow Transplant. 2014;20(3):425-9.
14. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Marnero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.
15. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-8.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-06.
18. Klein JP, Moeschberger ML. Survival Analysis: Statistical Methods for Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag; 2003.
19. Cox DR. Regression model and life tables. J R Stat Soc B. 1972;34(2):187-200.
20. Peffault de Latour R, Calado RT, Busson M, Abrams J, Adoui N, Robin M, et al. Ageadjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood. 2012;120(16):3353-9.
21. Christiansen DH, Andersen MK, Pedersen- Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001; 19(5):1405-13.
22. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, et al. Five-group cytogenetic risk classification, monosomal karyotype and outcomes after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120(7):1398-08.
23. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-19.
24. Peinemann F, Grouven U, Kroger N, Bartel C, Pittler MH, Lange S. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One. 2011;6(4):e18572.
25. Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2008;41(1):45-50.
26. Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011;118(9):2618-21.
27. Maury S, Balere-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92(5):589-96.
28. Lee JW, Cho BS, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. The outcome of unrelated hematopoietic stem cell transplants with total body irradiation (800 cGy) and cyclophosphamide (120 mg/kg) in adult patients with acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2011; 17(1):101-8.